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Purpose: This study aimed to evaluate the clinical efficacy of enzalutamide in chemotherapy-naïve metastatic castration-resistant 
prostate cancer (mCRPC) patients using real-world data from Korean patients.
Materials and Methods: We retrospectively reviewed the medical records of 199 chemotherapy-naïve patients with mCRPC at 13 
tertiary centers in Korea between 2014 and 2017. All patients received enzalutamide daily and 89 patients received concurrent an-
drogen deprivation therapy (ADT). 
Results: The median age of the patients was 74 years. Initial results showed that 81.5% of the patients had Gleason score ≥8 and 
33.3% of the patients had European Cooperative Oncology Group Performance Status 0. The overall mortality rate was 12%. The 
median OS was not archieved and 76.7% of patients were alive at 30 months. Median time until PSA progression was 6 months. The 
overall survival rate at 2 years was significantly higher (84.6% vs. 71.7%, p=0.015) and the duration of PSA progression-free survival 
was significantly longer (8.0 vs. 4.6 months, p=0.008) in patients receiving concurrent ADT than in those receiving enzalutamide 
alone. The incidence of adverse events of grade 3 or higher was 1.7%. Multivariate Cox proportional hazard analysis indicated that 
ADT administered concurrently with enzalutamide significantly improved the overall survival (hazard ratio, 0.346; 95% confidence 
interval, 0.125–0.958). 
Conclusions: Enzalutamide is effective and safe for chemotherapy-naïve patients with mCRPC. Furthermore, the overall survival 
was significantly higher in patients receiving enzalutamide and concurrent ADT than in patients receiving enzalutamide alone.
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In 2012, prostate cancer was the fifth most commonly 
diagnosed malignancy in Korean men [1]. The incidence of 
prostate cancer is lower in Korea than in western countries 
[2]. However, a steady increase has been observed in the 
prevalence of prostate cancer in Korea during the last de-
cade [3]. Progression of prostate cancer leads to metastasis, 
and most patients respond to androgen deprivation therapy 
(ADT). However, patients develop resistance to ADT, and 
this condition is known as metastatic castration-resistant 
prostate cancer (mCRPC). Metastatic CRPC is defined by 
progression of cancer despite the effective lowering of serum 
testosterone levels to castrate levels [4]. Docetaxel plus pred-
nisone is the current standard of care for mCRPC in Korea, 
but this therapy has toxic effects and leads to the develop-
ment of  drug resistance [5]. Recent findings have shown 
that androgen receptor signaling plays an important role in 
CRPC, which suggests that inhibition of this pathway using 
non-cytotoxic therapies may confer a survival benefit. The 
results of the international, randomized, double-blind, phase 
3, PREVAIL trial in chemotherapy-naïve men showed that 
enzalutamide improves overall survival (OS) [6]. 
Results of the PREVAIL showed that treatment with 
enzalutamide showed positive outcomes on all secondary 
endpoints, including the time until the first skeletal-related 
event (SRE), soft-tissue response rate, time until prostate-
specific antigen (PSA) progression, and PSA response rate 
(≥50% decline), as well as patient-reported outcomes [6-9]. 
Enzalutamide was approved in Korea in June 2013 for use 
in men with CRPC post-chemotherapy based on the results 
of the AFFIRM trial. In May 2015, the indication was ex-
panded to include men with CRPC regardless of previous 
exposure to chemotherapy based on results of the PREVAIL 
trial [10]. This study aimed to evaluate the clinical results 
of enzalutamide in chemotherapy-naïve mCRPC patients 
using Korean, multicenter, real-world data and to compare 
them with the results of  the PREVAIL study. In Korea, 
continuous ADT for mCRPC patients was prohibited until 
January 2017; subsequently, concurrent ADT was allowed. 
Thus, we were able to analyze the efficacy of enzalutamide 
and concurrent ADT in the treatment of patients with che-
motherapy-naïve mCRPC. This study will support evidence 
to the current recommendations for continuing luteinizing 
hormone-releasing hormone (LHRH) therapy, which can 
improve the benefits of enzalutamide treatment in patients 
with chemotherapy-naïve mCRPC.
MATERIALS AND METHODS
1. Study design and patients
We retrospectively reviewed the medical records of 
199 chemotherapy-naïve patients with mCRPC at 13 ter-
tiary centers in Korea between 2014 and 2017. The exclu-
sion criteria were previous docetaxel chemotherapy, brain 
metastasis, or epidural disease. Patients who had already 
received enzalutamide treatment included in a clinical trial 
were excluded. Enzalutamide was administered daily at an 
initial dose of 160 mg, and ADT was administered in a con-
ventional manner. Unlike the PREVAIL trial, our trial did 
not have stringent eligibility criteria to reflect a real clini-
cal environment. The endpoint of this trial was OS, which 
was defined as the time from the start of treatment to any 
cause of death. We followed the protocol mentioned in the 
PREVAIL trial for the definition of response criteria and 
endpoints in Prostate Cancer Clinical Trial Working Group 2, 
Solid Tumor Version 1.1 (RECIST 1.1). For patients with a de-
creased PSA levels at week 13, the time to PSA progression 
was defined as the day on which PSA levels increased by 
more than 25% and the day on which PSA levels increased 
by at least 2 ng/mL over a minimum of two consecutive 
days. For patients without a decreased PSA levels at week 
13, the day on which PSA levels increased by more than 
25% and the day on which a 2 ng/mL increase over baseline 
levels was recorded was identified as the second consecutive 
value. Radiographic progression-free survival (rPFS) was 
defined as the time of initial objective evidence of radiologi-
cal progression or death. Radiographic progression is defined 
as the appearance of two or more new lesions according to 
RECIST 1.1 or on the bone scan for soft tissue disease. SREs 
are defined as the events that necessitate changes in chemo-
therapy, such as radiation therapy or bone surgery for the 
treatment of pathological fractures, spinal cord compression, 
or bone pain. Advent events (AEs) were evaluated according 
to National Cancer Institute Common Terminology Criteria 
for Adverse Events, version 4.0.3.
2. Data collection and statistical analysis
The research data were collected using the Research 
Electronic Data Capture (REDCap) program designed to sup-
port data capture. We performed the chi-square or Mann–
Whitney U tests to compare the categorical and continuous 
variables, respectively, between the two groups. PFS and OS 
were analyzed using Kaplan–Meier methods and log-rank 
tests. Univariate and multivariate Cox proportional hazards 
regression analyses were performed to assess the association 
between baseline parameters and OS. All p-values correspond 
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to two-sided tests, with p-values <0.05 considered statistically 
significant. PSA response summaries were presented as per-
centages of patients who showed a decrease in PSA levels by 
more than 50% or 90%, respectively, from baseline to lowest 
point, and were visualized using waterfall plots. AEs were 
described as the rate of all grade or grade ≥3 events.
3. Ethical statement 
This study was approved by the Institutional Review 
Boards at each participating center (representative IRB: 
Seoul National University Hospital IRB no. H-1604-099-755). 
Subjects provided written informed consent, and the study 
was performed according to the Declaration of Helsinki.
RESULTS
Demographic features and disease characteristics of pa-
tients are shown in Table 1 [6,10]. Initial results showed that 
81.5% of the patients had Gleason score (GS) ≥8 and 33.3% of 
the patients had European Cooperative Oncology Group Per-
formance Status (ECOG PS) 0. Eighty-nine patients (44.9%) 
received concurrent ADT. Median follow-up is 9.4 months 
(interquartile range, 3.9–13.5 months). The overall mortality 
rate was 12%. The Kaplan–Meier curves for OS and rPFS 
are shown in Fig. 1 [6,10]. Median OS, median rPFS, median 
time until chemotherapy, median time until first SRE was 
not reached until our analysis (Fig. 1, Table 2) [6,10]. Median 
time until PSA progression was 6 months (Table 2) [6,10]. Af-
ter enzalutamide treatment, 35.2% of patients received more 
than one systemic chemotherapy (Table 3) [6,10]. The median 
OS was not achieved and 76.7% of patients were alive at 
30 months. In a Kaplan–Meier curve with 95% confidence 
interval (CI), OS was 0.84 (95% CI, 0.76–0.91) at 12 months 
and 0.77 (95% CI, 0.67–0.87) at 24 months (Supplementary 
Fig. 1). The results of the univariate Cox proportional haz-
ard analysis for OS showed that concurrent ADT, ECOG 
PS, and baseline PSA levels were significant predictors of 
OS (Table 4). Results of multivariate analysis showed that 
enzalutamide and concurrent ADT significantly improved 
the OS (hazard ratio, 0.346; 95% CI, 0.125–0.958). The median 
duration of enzalutamide treatment was 5 months, and the 
incidence of AEs of grade 3 or higher was 1.7% (Table 5) [6,10]. 
The Kaplan–Meier curves for OS, PSA PFS, and rPFS af-
ter concurrent ADT are shown in Fig. 2. The OS by 2 years 
was significantly improved with concurrent ADT (84.6% 
vs. 71.7%, p=0.015). In addition, patients receiving concurrent 
ADT showed a significant improvement in PSA PFS (8.0 vs. 
4.6 months, p=0.008). However, rPFS at 2 years was not dif-
Table 1. Baseline patient and disease characteristics
Characteristic 
PREVAIL (n=1,717) [6] PREVAIL Korean (n=78) [10] Current study 
(n=199)ENZA (n=872) Placebo (n=845) ENZA (n=40) Placebo (n=38)
Median age (y) 72 (43–93) 71 (42–93) 71 (56–83) 67 (42–85) 74 (51-94)
Median body weight (kg) 83.1 82.8 67.0 70.5 66.0
Body mass index (kg/m2) 27.5 27.5 24.4 25.5 24.2
Gleason score ≥8 at initial diagnosis 424 (50.6) 423 (52.4) 30 (81.1) 31 (81.6) 145 (81.5)
   Missing 34 37 3 21
ECOG PS grade=0 584 (67.0) 585 (69.2) 22 (55.0) 29 (76.3) 62 (33.3)
   Missing 13
Median PSA (ng/mL) 54.1 44.2 25.4 26.2 51.6
Median LDH (IU/L) 185.0 185.0 191.0 184.5 333.0
Prior radical prostatectomy (%) 226 (25.9) 225 (26.6) 11 (27.5) 4 (10.5) 36 (18.2)
   Missing 1
Bone disease (%) 741 (85.0) 690 (81.7) 36 (90.0) 30 (78.9) 160 (82.5)
   Missing 5
≥20 bone metastases 145 (16.6) 150 (17.8) Unknown Unknown 15 (9.9)
   Missing 47
Soft-tissue disease (lymph node, visceral, or other) 517 (59.3) 504 (59.6) 22 (55.0) 22 (57.9) 110 (58.5) 
   Missing 11
Concurrent ADT 872 (100.0) 845 (100.0) 40 (100.0) 38 (100.0) 89 (44.9)
   Missing 1
Values are presented as median (range), number only, or number (%). 
ENZA, enzalutamide; ECOG PS, European Cooperative Oncology Group Performance Status; PSA, prostate-specific antigen; LDH, lactate dehydro-




ferent in patients receiving concurrent ADT (71.8% vs. 68.4%, 
p=0.154). The waterfall plot of the change in PSA levels in 
patients receiving concurrent ADT is shown in Fig. 3. To 
compare Korean real-world data with the result of the PRE-
VAIL study, we described data of PREVAIL study in Table 1, 
Table 2, Table 3, Table 5 and Fig. 1 [6,10].
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Fig. 1. Kaplan–Meier survival curves for (A) overall survival and (B) radiographic progression-free survival in PREVAIL study [6], in PREVAIL Korean post hoc 
analysis [10], and in this study.
Table 3. Subsequent anti-neoplastic and endocrine therapies
Type of treatment
PREVAIL (n=1,717) [6] PREVAIL Korean (n=78) [10] Current study 
(n=199)ENZA (n=872) Placebo (n=845) ENZA (n=40) Placebo (n=38)
Any systemic treatment 382 (43.8) 642 (76.0) 7 (17.5) 25 (65.8) 70 (35.2)
 Missing 23
Antineoplastic agent 308 (35.3) 515 (60.9) 6 (15.0) 22 (57.9) 40 (22.7)
Docetaxel 286 (32.8) 479 (56.7) 5 (12.5) 22 (57.9) 34 (19.3) 
Abiraterone acetate 179 (20.5) 385 (45.6) 1 (2.5) 4 (10.5) 9 (5.1)
Cabazitaxel 51 (5.8) 110 (13.0) 0 (0.0) 3 (7.9) 2 (1.1)
Mitoxantrone 5 (0.6) 9 (1.1) 0 (0.0) 1 (2.6) 0 (0.0)
Duplicated count was allowed. 
ENZA, enzalutamide. 
Table 2. Summary of oncologic outcomes
Variable
PREVAIL (n=1,717) [6] PREVAIL Korean (n=78) [10] Current study 
(n=199)ENZA (n=872) Placebo (n=845) ENZA (n=40) Placebo (n=38)
Median time until chemotherapy (mo) 28.0 10.8 NYR 11.2 NYR
   HR (95% CI) 0.35 (0.30–0.40) 0.21 (0.08–0.51)
Median time until PSA progression (mo) 11.2 2.8 11.1 2.9 6.0
   HR (95% CI) 0.17 (0.15–0.20) 0.31 (0.17–0.56)
Median time until first SRE (mo) 31.1 31.3 NYR 20.1 NYR
   HR (95% CI) 0.72 (0.61–0.84) 1.40 (0.46–4.33)
PSA decline of
   ≥50% from baseline (n/total n; %) 666/854 (78.0) 27/777 (3.5) 28/40 (70.0) 4/38 (10.5) 139/187 (74.3)
   ≥90% from baseline (n/total n; %) 400/854 (46.8) 9/777 (1.2) Unknown Unknown 88/187 (47.1)
ENZA, enzalutamide; HR, hazard ratio; CI, confidence interval; PSA, prostate-specific antigen; SRE, skeletal-related event; NYR, not yet reached.
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DISCUSSION 
The effects of enzalutamide observed in our study with 
asymptomatic or mildly symptomatic Korean chemotherapy-
naïve patients with mCRPC were consistent with those ob-
served in the study population of the PREVAIL trial [6,10].
However, the baseline disease characteristics of the sub-
jects in our study were different from those of the subjects 
in the PREVAIL trial, which may be because of the differ-
ences in real clinical practice. A high percentage of Korean 
patients had a GS of at least 8, which indicates a high dis-
ease burden. Our finding was consistent with that observed 
in the PREVAIL trial in that 50.6% and 81.1% patients 
receiving enzalutamide among the overall population and 
in Korean subgroup, respectively, has a GS ≥8 [10]. Some dif-
ferences were observed in the characteristics of the disease 
between the real-world Korean patients and the subjects in 
the PREVAIL trial; these differences may be related to dif-
ferences in ethnicity. Compared to the overall study popula-
tion of the PREVAIL trial, a larger proportion of Korean 
patients had poor PS. A lower proportion of patients in our 
study had ECOG PS=0 (33.3% vs. 67.0% in the PREVAIL 
study). In clinical practice, the physicians, patients, and rela-
tives of  chemotherapy-naïve patients with mCRPC with 
poor PS are reluctant to undergo chemotherapy. Therefore, 
they prefer treatment with enzalutamide despite its high 
cost before commencing chemotherapy. Thus, this finding 
may explain why our data showed that a high proportion 
of Korean patients had poor performance status. Korean 
patients receiving enzalutamide had a short median time 
Table 4. Cox regression analysis for overall survival
Variable
Univariate Multivariate
HR 95% CI p-value HR 95% CI p-value
Age (y)
   <65 Reference
   ≥65 0.808 0.302–2.162 0.672
ECOG PS 
   0–1 Reference
   ≥2 2.993 1.160–7.723 0.023
No. of HT 
   ≤2 Reference
   >2 1.048 0.247–4.453 0.949
Type of progression at study entry 
   PSA only Reference
   Radiographic progression +/- PSA progression 0.699 0.350–2.020 0.699
No. of bone lesions
   <20 Reference
   ≥20 1.090 0.141–8.435 0.934
Lymph node involvement 
   No Reference
   Yes 0.943 0.415–2.139 0.888
Visceral metastasis
   No Reference
   Yes 1.170 0.342–4.006 0.802
Gleason score
   ≤7 Reference
   ≥8 6.059 0.818–44.86 0.078
Baseline PSA
   ≤Median Reference Reference
   >Median 2.517 1.084–5.840 0.032 2.507 0.958–6.563 0.061
Concurrent ADT 
   No Reference Reference
   Yes 0.335 0.133–0.845 0.020 0.346 0.125–0.958 0.041
HR, hazard ratio; CI, confidence interval; ECOG PS, European Cooperative Oncology Group Performance Status; HT, hormonal treatment; PSA, 




until PSA progression, and poor baseline characteristics and 
PS may be attributed to this result. In addition to baseline 
characteristics, concurrent ADT affects the OS. Unlike the 
patients in the PREVAIL trial, a larger proportion of Ko-
rean patients (55%) had did not receive concurrent ADT 
with enzalutamide in the clinical setting because the Korean 
medical insurance system prohibited continuous ADT for 
mCRPC until January 2017. Our results showed that ADT 
administered concurrently with enzalutamide improved the 
oncologic outcomes of  chemotherapy-naïve patients with 
mCRPC.
To date, no study has established evidence supporting 
continuation of LHRH therapy for CRPC [11]. Few studies 
have investigated the effects of termination of LHRH ther-
apy in patients with CRPC and, therefore, the current Euro-
pean guidelines recommend medical castration [12]. The Ko-
rean medical insurance system prohibited continuous ADT 
for mCRPC because of lack of evidence until January 2017. 
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Fig. 2. According to concurrent androgen deprivation therapy (ADT), Kaplan–Meier survival estimates for (A) overall survival and (B) time to prostate-
specific antigen (PSA) progression-free survival, and (C) radiographic progression-free survival.
Table 5. Summary of adverse events
Parameter
PREVAIL (n=1,715) [6] PREVAIL Korean (n=78) [10] Current study 
(n=199)ENZA (n=871) Placebo (n=844) ENZA (n=40) Placebo (n=38)
Median duration of treatment (mo) 16.6 4.6 13.0 5.1 5.0
Any AEs 844 (96.9) 787 (93.2) 37 (92.5) 30 (78.9) 59 (34.9)
   Missing 30
Serious AEs 279 (32.0) 226 (26.8) 14 (35.0) 3 (7.9) 3 (1.7)
   Missing 22
Grade ≥3 AEs 374 (42.9) 313 (37.1) 13 (32.5) 4 (10.5) 3 (1.8)
   Missing 30
Drug-related grade ≥3 AEs 67 (7.7) 54 (6.4) 0 (0.0) 0 (0.0) 3 (1.7)
   Missing 23
Most common AEs
   Musculoskeletal pain 87 (10.0) 73 (8.6) 4 (10.0) 2 (5.3) 8 (4.7)
   Fatigue 310 (35.6) 218 (25.8) 8 (20.0) 4 (10.5) 6 (3.6)
   Decreased appetite 158 (18.1) 136 (16.1) Unknown Unknown 5 (3.0)
   Constipation 193 (22.2) 145 (17.2) 6 (15.0) 2 (5.3) 2 (1.2)
   Diarrhea 142 (16.3) 119 (14.1) Unknown Unknown 2 (1.2)
   Hypertension 117 (13.4) 35 (4.1) Unknown Unknown 2 (1.2)
   Hot flush 157 (18.0) 65 (7.7) 5 (12.5) 2 (5.3) 2 (1.2)
   Headache 91 (10.4) 59 (7.0) Unknown Unknown 2 (1.2)
   Back pain 235 (27.0) 187 (22.2) 7 (17.5) 3 (7.9) 1 (0.6)
   Nausea 201 (23.1) 190 (22.5) 6 (15.0) 4 (10.5) 1 (0.6)
   Asthenia 113 (13.0) 67 (7.9) Unknown Unknown 1 (0.6)
   Upper respiratory infection 53 (6.1) 30 (3.6) 8 (20.0) 3 (7.9) 0 (0.0)
Values are presented as number only or number (%). 
ENZA, enzalutamide; AE, adverse event.
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Continuation of LHRH therapy may cause considerable side 
effects and unnecessary expenses [13]. Results from previous 
clinical trials indicate that castration offers only a marginal 
survival benefit [14,15]. Taylor et al. [14] reported the results 
of a retrospective study, which showed a significant mar-
ginal survival benefit for patients continuing an LHRH 
agonist along with anthracycline, platinum, or ketoconazole 
treatment for mCRPC. However, a consensus remains to be 
achieved about the continuation of LHRH treatment. Anal-
ysis of 5 Southwest Oncology Group phase II chemotherapy 
trials conducted in the 1990s failed to show an obvious ad-
vantage of continuous ADT in terms of response to cytotoxic 
chemotherapy or OS in patients with CRPC [15]. The results 
of another retrospective study of 78 patients failed to show 
a survival benefit of docetaxel and concurrent ADT in pa-
tients with CRPC [16]. However, it could be an underpow-
ered study because of the small number of patients. Lee et 
al. [16] found that serum testosterone levels did not recover 
to those observed in noncastrated individuals in most pa-
tients after withdrawal of ADT for the entire duration of 
chemotherapy. A similar phenomenon was observed in men 
with hormone-sensitive prostate cancer, in which approxi-
mately half of the patients who received ADT for a long-
term remained castrated at 2.5 years after ADT cessation [17]. 
Results of previous studies indicate that serum testosterone 
levels remain low after long-term treatment with LHRH 
agonists [18-20]. Therefore, cessation of LHRH therapy may 
have only little clinical relevance since serum testosterone 
levels remain low and may not affect proliferation of cancer 
cells. However, unlike serum testosterone levels, serum LH 
levels recover after several weeks to months after cessation 
of LHRH therapy [18-20]. Cessation of LHRH therapy leads 
to rapid recovery of LH levels after a median of 58 days to 
4.5 months, even after long-term medical castration [18,19]. 
Apart from its action on the testes and adrenal glands, LH 
acts directly on prostate cancer cells via LH-specific receptors 
and increases the expression of several key steroidogenic en-
zymes [21]. Administration of abiraterone alone increases the 
LH [22]. To date, the SPARE trial (NCT02077634) is the only 
trial that provides further insights into the complex hor-
monal changes that occur after treatment with abiraterone 
with or without concurrent LHRH therapy [23]. The SPARE 
trial is investigating the role of continuation of LHRH ther-
apy when starting treatment with abiraterone in patients 
with asymptomatic or mild symptomatic chemotherapy-
naïve CPRC. To date, no study has investigated the efficacy 
of enzalutamide and concurrent ADT in the treatment of 
chemotherapy-naïve mCPRC. Therefore, the results of our 
trial provide important evidence based on unique data. 
This study is subject to the usual limitations inherent 
with retrospective design and data collection. The follow-
up period of this study was relatively short. Further, some 
missing values are another weakness of the data. The rate 
of AEs in our study was lower than those in the PREVAIL 
trial, which may be because of the retrospective study de-
sign. The advantages of our study are that we analyzed real-
world data from multiple institutions. Furthermore, the pri-
mary endpoint was OS, which is relatively objective and less 
confounded even in a retrospective study. Thus, our results 
provide novel data about the efficacy of enzalutamide and 
concurrent ADT for the treatment of men with chemother-
apy-naïve mCRPC due to the previous medical environment 
in Korea, in which continuous ADT therapy for mCRPC 
patients was prohibited.
CONCLUSIONS
A higher proportion of  patients in our cohort study 
showed a GS ≥8 and poor ECOG performance status than 
those in the PREVAIL study, but the efficacy results in 
our study were similar to those in the PREVAIL study. 
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Fig. 3. Waterfall plot for prostate-specific 
antigen (PSA) response according to 





was also acceptable. Enzalutamide is effective and safe for 
chemotherapy-naïve patients with mCRPC in the real-world 
setting. Further, compared to enzalutamide alone, concur-
rent administration of ADT with enzalutamide significantly 
prolonged the survival. Thus, we recommend concurrent 
administration of ADT with enzalutamide for the treatment 
of chemotherapy-naïve patients with mCRPC. 
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